Research Team

  • Richard Martin, Denver, Colorado, USA,
  • Dirkje Postma, Groningen, The Netherlands
  • Nicholas Roche, Paris, France
  • Wim van Aalderen, The Netherlands
  • Richard Dekhuijzen, The Netherlands
  • Thys van der Molen, The Netherlands

Status: Active

Support: Teva

Registration:

Short Description

The aim of this study is to compare effectiveness (in terms of asthma control) of EF-ICS and SP-ICS therapies in patients from The Netherlands prescribed asthma therapy. In order to do so, we will compare the effectiveness of initiating ICS therapy as EF-HFA-BDP (Qvar®) pressurised metered dose inhaler (pMDI) or Ciclesonide vs. the most prescribed SP-ICS therapies in The Netherlands. The exact comparators were selected based on patient numbers receiving different ICS therapies within the supplied dataset and included FP and non-EF-HFA-BDP. The effects of increasing doses (≥50%) as EF or SP-ICS may also be evaluated as a separate cohort (step-up cohort), but a decision on whether analysing this cohort or not will be made based on review of the results obtained for the initiation cohort.

Documents and Publications

Protocol

Abstracts

Presentations

Final Publications

Additional Material